Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Glioblastoma

ClinicalTrials.gov lists 2,063 trials for Glioblastoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 120.

MeSH D005909 Neoplasms Neoplasm C04 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 620 Phase 1/2 Phase 1/2 281 Phase 2 Phase 2 582 Phase 2/3 Phase 2/3 15 Phase 3 Phase 3 92 Phase 4 Phase 4 8 Not applicable Not applicable 239 Observational Observational 210 Phase 1 Phase 1 620 Phase 1/2 Phase 1/2 281 Phase 2 Phase 2 582 Phase 2/3 Phase 2/3 15 Phase 3 Phase 3 92 Phase 4 Phase 4 8 Not applicable Not applicable 239 Observational Observational 210

Trials per phase (log scale)

1 more section with rows

2,063 of the 2,063 trials are tagged with Glioblastoma itself; the rest are tagged with a narrower condition beneath it.

Get the Glioblastoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Glioblastoma trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 13 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 109

1990: 1 trials (Phase 3 1) 1991: 1 trials (Phase 1 1) 1993: 2 trials (Phase 1/2 1, Phase 1 1) 1994: 6 trials (Phase 3 1, Phase 2 2, Phase 1 3) 1995: 5 trials (Observational 1, Phase 2 2, Phase 1 2) 1996: 10 trials (Not applicable 1, Phase 2 6, Phase 1 3) 1997: 11 trials (Phase 2 6, Phase 1/2 1, Phase 1 4) 1998: 15 trials (Not applicable 1, Phase 3 2, Phase 2 4, Phase 1/2 3, Phase 1 5) 1999: 21 trials (Observational 1, Phase 3 1, Phase 2 9, Phase 1/2 2, Phase 1 8) 2000: 28 trials (Phase 3 1, Phase 2 10, Phase 1/2 12, Phase 1 5) 2001: 31 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 13, Phase 1/2 6, Phase 1 7) 2002: 35 trials (Observational 1, Phase 3 2, Phase 2 9, Phase 1/2 9, Phase 1 14) 2003: 22 trials (Observational 1, Phase 3 1, Phase 2 13, Phase 1/2 1, Phase 1 6) 2004: 34 trials (Observational 4, Not applicable 1, Phase 3 4, Phase 2 11, Phase 1/2 5, Phase 1 9) 2005: 52 trials (Observational 2, Not applicable 3, Phase 3 4, Phase 2 20, Phase 1/2 8, Phase 1 15) 2006: 56 trials (Observational 6, Not applicable 3, Phase 3 5, Phase 2 23, Phase 1/2 9, Phase 1 10) 2007: 62 trials (Observational 5, Phase 3 3, Phase 2/3 1, Phase 2 32, Phase 1/2 7, Phase 1 14) 2008: 65 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 6, Phase 2 27, Phase 1/2 6, Phase 1 18) 2009: 67 trials (Observational 6, Phase 3 4, Phase 2 29, Phase 1/2 11, Phase 1 17) 2010: 76 trials (Observational 2, Not applicable 5, Phase 3 3, Phase 2 25, Phase 1/2 14, Phase 1 27) 2011: 71 trials (Observational 4, Not applicable 3, Phase 3 3, Phase 2 26, Phase 1/2 11, Phase 1 24) 2012: 57 trials (Observational 4, Not applicable 6, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 18, Phase 1/2 9, Phase 1 16) 2013: 73 trials (Observational 6, Not applicable 12, Phase 3 2, Phase 2 19, Phase 1/2 11, Phase 1 23) 2014: 76 trials (Observational 8, Not applicable 9, Phase 3 2, Phase 2/3 2, Phase 2 20, Phase 1/2 8, Phase 1 27) 2015: 69 trials (Observational 7, Not applicable 9, Phase 3 5, Phase 2/3 1, Phase 2 22, Phase 1/2 8, Phase 1 17) 2016: 89 trials (Observational 13, Not applicable 5, Phase 3 2, Phase 2 22, Phase 1/2 14, Phase 1 33) 2017: 85 trials (Observational 12, Not applicable 13, Phase 3 3, Phase 2/3 1, Phase 2 23, Phase 1/2 12, Phase 1 21) 2018: 109 trials (Observational 15, Not applicable 14, Phase 3 6, Phase 2/3 4, Phase 2 17, Phase 1/2 14, Phase 1 39) 2019: 79 trials (Observational 9, Not applicable 13, Phase 4 1, Phase 3 2, Phase 2/3 2, Phase 2 19, Phase 1/2 9, Phase 1 24) 2020: 98 trials (Observational 6, Not applicable 18, Phase 3 3, Phase 2/3 1, Phase 2 24, Phase 1/2 13, Phase 1 33) 2021: 88 trials (Observational 14, Not applicable 17, Phase 2 21, Phase 1/2 11, Phase 1 25) 2022: 107 trials (Observational 13, Not applicable 16, Phase 4 2, Phase 3 4, Phase 2 17, Phase 1/2 12, Phase 1 43) 2023: 104 trials (Observational 20, Not applicable 15, Phase 3 1, Phase 2 19, Phase 1/2 15, Phase 1 34) 2024: 105 trials (Observational 20, Not applicable 19, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 28, Phase 1/2 10, Phase 1 21) 2025: 105 trials (Observational 12, Not applicable 24, Phase 4 1, Phase 3 7, Phase 2 19, Phase 1/2 8, Phase 1 34)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 110
2025 105
2024 105
2023 104
2022 107
2021 88
2020 98
2019 79
2018 109
2017 85

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 120 trials starting in 2026 and about 110 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 292 trials still running at the 2026-10-09 snapshot; registered median of 40 months across 1,227 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Glioblastoma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 620
Phase 1/2 281
Phase 2 582
Phase 2/3 15
Phase 3 92
Phase 4 8
Not applicable 239
Observational 210
Expanded access 16

How many Glioblastoma trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 89
Recruiting 303
Enrolling by invitation 7
Active, not recruiting 163
Available 6

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Glioblastoma trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 120
Novartis Pharmaceuticals 20
European Organisation for Research and Treatment of Cancer - EORTC 19

Which drugs are being tested for Glioblastoma? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 35
Irinotecan 30
NIVOLUMAB 29
Cytoxan 19

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SOC: Temozolomide 352
Radiation Therapy 130
Bevacizumab 1 123
Lomustine Pill 44
Radiotherapy 42

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Glioblastoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Seizure 887 181
Fatigue 354 98
Platelet count decreased 352 50
Headache 347 121
Vomiting 272 105

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Glioblastoma? (1,051)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Anti-PD-1 and anti-PD-L1 antibodies for glioma. The Cochrane database of systematic reviews 2025 Yes
MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma. Cell 2025 Yes
S100A proteins show a spatial distribution of inflammation associated with the glioblastoma microenvironment architecture. Theranostics 2025 Yes
Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study. Clinical cancer research : an official journal of the American Association for Cancer Research 2025 Yes
The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma. BMC cancer 2025 Yes

Showing 5 of 1,051 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (21)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Glioblastoma Annual incidence 1-9 / 100 000 United States US Exact
Glioblastoma Annual incidence 1-9 / 100 000 United States US Exact
Glioblastoma Annual incidence 1-9 / 100 000 United States US Unspecified
Glioblastoma Annual incidence 1-9 / 100 000 Worldwide Not stated Exact
Glioblastoma Point prevalence 1-9 / 100 000 Worldwide Not stated Unspecified

Showing 5 of 21 prevalence observations.

Start your 14-day trial Email me all 21 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Glioblastoma 360 Exact Orphanet Rare Disease Ontology (ORDO)
Glioblastoma 360 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages